Published in final edited form as:

Mov Disord. 2009 October 15; 24(13): 1893–1901. doi:10.1002/mds.22712.

Launching Invasive, First-in-Human Trials against Parkinson's Disease: Ethical Considerations

Jonathan Kimmelman¹, Alex John London², Bernard Ravina³, Tim Ramsay⁴, Mark Bernstein⁵, Alan Fine⁶, Frank W. Stahnisch⁷, and Marina Elena Emborg⁸

¹Biomedical Ethics Unit / Department of Social Studies of Medicine / McGill University / 3647 Peel Street, Montreal, QB H3A 1X1, Canada jonathan.kimmelman@mcgill.ca ph: (514) 482-8362 / Fax: (514) 398-8349

²Dept. of Philosophy / Carnegie Mellon University / Pittsburgh, PA 15213 / USA

³Neurology, MIND Unit / University of Rochester School of Medicine / 1351 Mt Hope Ave suite 223 Rochester NY 14620 USA

⁴Ottawa Health Research Institute, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6 Canada

⁵Division of Neurosurgery, Toronto Western Hospital, University of Toronto, 399 Bathurst Street, Toronto, Ontario M5T 2S8 Canada

⁶Dept. of Physiology & Biophysics / Dalhousie University Faculty of Medicine / Halifax, Nova Scotia B3H 1X5 Canada

⁷Department of Community Health Sciences / University of Calgary / Heritage Medical Research Building RG30 / 3330 Hospital Drive NW/ Calgary, AB T2N 4N1 Canada

⁸Preclinical Parkinson's Research Program / Wisconsin National Primate Research Center and Department of Medical Physics / University of Wisconsin – Madison /1220 Capitol Court, Madison, WI 53705 USA. emborg@primate.wisc.edu

Abstract

The decision to initiate invasive, first-in-human trials involving Parkinson's disease presents a vexing ethical challenge. Such studies present significant surgical risks, and high degrees of uncertainty about intervention risks and biological effects. We argue that maintaining a favorable risk-benefit balance in such circumstances requires a higher than usual degree of confidence that protocols will lead to significant direct and/or social benefits. One critical way of promoting such confidence is through the application of stringent evidentiary standards for preclinical studies. We close with a series of recommendations for strengthening the internal and external validity of preclinical studies, reducing their tendency toward optimism and publication biases, and improving the knowledge base used to design and evaluate preclinical studies.

Correspondence to: Jonathan Kimmelman; Marina Elena Emborg.

Author Roles:

Research Project: (Initial Conception: JK; Design: JK, AJL, MEE, BR, TR; Organization: JK; Data Collection: JK, MEE; Execution and Content of Workshop: All)

Statistical Analysis: Not applicable

Manuscript: (Writing of the first draft: JK; Review, Critique, and Revision: All)

Keywords

Research ethics; clinical trials; Parkinson's disease; Preclinical research; translational research; phase 1

1. Introduction

A major objective in Parkinson's disease (PD) research is the development of strategies to halt degeneration and/or restore the function of dopaminergic and other neurons. Among the approaches being tested are various small molecule drugs,ⁱ trophic factors,ⁱⁱ deep brain stimulation,ⁱⁱⁱ cell transplantation, and gene transfer.^{iv}

Ethical discussion of translational PD trials has tended to center on sham surgery,^v quality of informed consent,^{viii} subject selection,^{ix} and the use of fetal tissues.^x Nevertheless, a perhaps more fundamental question remains uncharted: when is it ethical to initiate invasive first-in-human (FIH) PD trials? Decisions to launch such trials are often marked by controversy. To date, three gene transfer strategies have been reviewed by the Recombinant DNA Advisory Committee. All received full public review, signaling novelty and ethical concerns.^{xi} The first received a particularly skeptical hearing,^{xii} and when this trial was initiated, several researchers castigated the investigators as "crazy," venturing into "terra incognita,"^{xiii} and "raising hopes in people with minimal evidence of benefits."^{xiv}

In November 2007, the Novel Neurotechnologies Ethics Research Group convened a workshop at McGill University to discuss the ethics of initiating invasive FIH PD trials. The analysis and recommendations that follow emerged from this meeting.

2. Methods

Two of us (JK and AJL, both ethicists) drafted a statement outlining objectives of the workshop. We then sought input from a preclinical researcher (MEE). After refining our statement, we invited another preclinical researcher (AF), a neurologist clinician / researcher (BR), an epidemiologist (TR), a neurosurgeon / researcher (MB), and a neuroscience historian (FS). Participants were selected on the basis of their interest in neurology translational research ethics. To ensure focused discussions, the pre-workshop statement was refined by invitees. The workshop was held on November 9, 2007; after a series of presentations and discussion, areas of consensus were identified. Except where noted, participants were in agreement about the analysis and recommendations presented here.

3. The Central Ethical Challenge of When to Initiate Trials

The core ethical challenges surrounding the initiation of invasive PD studies derive from the nature, probability, and indeterminacy of study risks. In particular, PD trials target the brain, and as "*the* organ of our personhood,"^{xv} adverse events have the potential to disrupt those features that make us who we are: language, memory, cognition, and identity.

Surgical Risk and PD Trials

PD trials are somewhat unusual because they involve a relatively high baseline level of risk, prior to the delivery of investigational agents. Whereas administration of small molecule drugs involves minimal risk, invasive PD studies involve inoculations to the brain. Based on studies examining complication rates associated with analogous surgical procedures in similar brain regions, risk of surgery-related permanent neurological deficits are on the order of 0.5 – 1% per inoculation.^{xvixvixvixvixvix} This might appear modest when compared against

phase 1 oncology studies (these involve 14% risk of grade 4 adverse events),^{xxi} but two additional factors must be considered. First, many PD protocols involve multiple injections; assuming somewhat conservatively that permanent neurological deficit risk is 0.5% per inoculation, four injections present almost 2.0% risk (in comparison, risk of irreversible adverse events in phase 1 oncology studies is approximately 1.5%^{xxi}). Second, these represent baseline levels of risk that are present before investigational agents are even received (contrast this with phase 1 cancer studies, where study risk normally derives from the study drug itself).

Investigational Agents, Risk, and Uncertainty

Uncertainty presents another important challenge for PD FIH studies. Experimental agents employed in invasive PD studies often have characteristics (e.g. potential vector immunogenicity) that limit the reliability of animal models for risk determination.^{xxiixxiii} Impairments in brain processes such as cognition are also difficult to model preclinically. Furthermore, though nonhuman primate toxicology studies play a crucial role in risk assessment, sample sizes and time horizons enable the detection of only high frequency, immediate, and catastrophic events. Our review of five well-known gene transfer and neurotrophic factor trials^{xxivxxvxxvixxviixxviii} found that, on average, investigators used 20 nonhuman primates in preclinical studies; two of these trials appear to have been based on preclinical studies for which the last time point was eight months (Table 1).^{xxix}

The Ethical Approach to Uncertainties

We believe that this high uncertainty should affect the appraisal of risk. It should translate to a presumption that study risks exceed numeric “best-estimates” provided by preclinical studies. This position is justified on the grounds that risk estimates from preclinical studies will tend, at best, to have wide confidence intervals and, at worst, will have limited predictive value. This proposal reflects the fact that the full range of adverse events is not known, and that their probability might be higher than anticipated.^{xxx xxxi}

4. Ethical Justification of Risk in FIH, Novel Intervention Studies

Numerous influential statements on research ethics underscore the importance of preclinical studies.^{xxxiixxxiii} For example, the CIOMS guidelines state “clinical testing must be preceded by adequate laboratory or animal experimentation to demonstrate a reasonable probability of success without undue risk.”^{xxxiv} This suggests that safety is an insufficient condition for launching human studies; study interventions must also have shown evidence of promise in laboratory studies. However, there is no consensus on either the quantity or quality of preclinical evidence necessary to justify a human study.

Evidentiary Standards

We believe that the risks of invasive PD FIH studies create exacting demands on the quantity and quality of preclinical evidence. This position is rooted in the requirement that risks and benefits must be favorably balanced in clinical research. In contrast, where study risks are moderate or minor, evidentiary standards need not be as stringent.

Many would question whether interventions used in FIH PD trials can be plausibly viewed as presenting a prospect of direct medical benefit. Granting for the moment that they do, it is nevertheless axiomatic within medicine that potentially harmful and difficult to reverse interventions should be undertaken only where there is a reasonably high degree of confidence that they offer therapeutic benefit. This favors stringent evidentiary standards for preclinical studies.

Risks in clinical trials are also ethically justified by the prospect of producing generalizable knowledge. With greater risk comes the obligation that studies present proportionately greater probability of producing knowledge benefits. We contend that trials founded on a sound evidence base will tend to have stronger claims to scientific value than those supported by weak evidence.

This claim rests on the following logic: the value of an experiment is partly a function of the confidence in the veracity of a hypothesis that an experiment engenders in the expert community. Experiments that can exclude competing explanations for results will produce greater confidence in the veracity of a study hypothesis than those that exclude fewer alternatives. For example, clinicians interpreting randomized controlled trial results tend to form stronger beliefs about a drug's efficacy if treatment allocation during the trial is concealed, because this excludes a competing explanation—that observer bias explains a “positive” trial result.^{xxxv}

Novel interventions rarely translate smoothly into clinical applications, especially for CNS disorders.^{xxxvixxxviiixxxviii} This is documented by the negative results of multiple randomized trials testing disease-modifying strategies for PD^{xxxixxl}, stroke^{xlxl} and other neurodegenerative diseases.^{xlxlxliv} A central question guiding the clinical translation of an invasive PD trial is whether negative outcomes will be informative. A critical ingredient in appraising the value of a null result is whether obvious competing explanations can be excluded. For example, if observer bias may have produced exaggerated treatment effects in preclinical studies, a null human result will be less informative.

In conclusion, preclinical researchers should reduce uncertainty where it is feasible to do so. Where preclinical studies can either limit uncertainty surrounding the properties of an intervention or weaken the plausibility of competing explanations for observations, FIH studies can make a stronger claim to producing scientifically meaningful outcomes. Preclinical data thus become an essential feature in deciding the risk-benefit balance of FIH trials.

5. Improving the Preclinical Evidence Base in Invasive PD Studies

What practices should investigators use in preclinical studies to enhance the scientific and/or therapeutic promise of FIH studies? When reviewing proposals, what elements should IRBs, funding agencies, and policy-makers expect? The remainder of our analysis is directed towards describing methodologies and practices in preclinical research that we believe would greatly enhance the ethical justification for initiating invasive FIH studies (Table 2).

Maximizing Internal Validity

Clinical research has evolved a series of methodological practices aimed at maximizing internal validity. As extensively documented in stroke research, these practices have permeated preclinical research to only a limited degree.^{xlxlvi} The first is *a priori* power calculation. These are almost never reported in PD preclinical studies. Though expense and burden severely constrain sample size for non-human primate studies, the absence of power calculations seems harder to defend where studies involve lesioned rats. Stating an *a priori* hypothesis, and powering a study accordingly, helps discourage researchers from expanding their samples sizes or manipulating definitions of efficacy to attain “significant” results.

PD preclinical studies also rarely report the use of random treatment allocation. Of 22 published preclinical studies used to support human GDNF and/or gene transfer studies against Parkinson's, only four reported randomization. This is lower than reported in other preclinical literatures.^{xlviixlvi} In a systematic review of 290 animal studies, non-randomized

studies had a 3.4 times higher odds of showing a positive treatment effect compared with studies that used randomization.^{xlvi} We acknowledge that simple randomized treatment allocation may not always be the best strategy in PD: it will often be more useful to balance groups on the basis of pre-treatment performance on key outcome measures, and then assign treatment randomly within these groups.

Blinded treatment allocation is also necessary to avoid subtle differences in the handling of animals. In one meta-epidemiological study involving preclinical studies of stroke interventions, studies that did not mask investigators to allocation produced significantly larger treatment effects than those that did.^{xlix} However, another procedure—blinded or automated outcome assessment—seems almost universally accepted in PD preclinical research (only three of 22 preclinical studies did not report using either).

Another crucial variable is the treatment of missing data. Given the small sample size in many preclinical studies, how missing data are managed can significantly alter the outcome of statistical tests.

Maximizing External Validity

External validity issues are related to the models used in PD preclinical studies. Although spontaneous rodent models of PD are now available,^{li} researchers have typically relied on various injury-induced models, which mimic nigrostriatal dopamine deficiency but do not recapitulate the slow, progressive degenerative or pathophysiological nature of PD. Thus, a typical PD neuroprotection study administers a putative neuroprotective agent before or at the same time as inducing an acute PD-like lesion. In contrast, human trials administer interventions in the context of a disease that is progressed and chronic.^{lii} The difference in disease states severely constrains the external validity of preclinical studies. A number of different animal models and clinical outcome measures are available for PD preclinical researchers,^{liii} and transgenic models should be given serious consideration when designing preclinical studies. At a minimum, investigators should justify their selection of models and outcome measures.

Preclinical studies should also correspond as much as possible with the methods used in clinical studies. For example, clinical studies should be performed without departing from delivery techniques, agent composition, or inoculation sites validated in preclinical studies.

Control of Optimism and Publication Biases

Optimism bias refers to an often unconscious tendency for researchers to present or interpret their data in a favorable light.^{liv} Optimism bias might pose particular challenges to translational research, because at the point where preclinical studies are underway, investigators have devoted many years to a research program. Though personal identification with a therapeutic strategy can fuel perseverance, it can also interfere with dispassionate appraisal of study findings.^{lv}

Publication bias (that is, a tendency to withhold reporting of unfavorable findings) presents yet another challenge to the credibility of preclinical study claims. By showing strong relationships between small sample sizes and large treatment effects, several meta-analyses of neurological preclinical studies show high rates of publication bias.^{xlvi}^{xlvi}

Preclinical research should therefore build mechanisms to check optimism and publication biases. Trial protocols should include critical reviews that place animal studies within a broader clinical context. Similar to a systematic review but broader in scope, a critical review should comprehensively summarize all existing literature that may be relevant to the results being reported. In contrast to a systematic review, the search strategy should be open-

ended rather than rigorously pre-specified. This is because preclinical animal studies that replicate a given study exactly are relatively rare. Rather, researchers should search for all possible studies that may be relevant, whether they are based on the same treatment in different animal models, related treatments in the same animal model, or even related treatments in different animal models. Given a propensity for optimism bias, critical review should aim at finding dissenting evidence (as opposed to supporting evidence). Preclinical reports and trial proposals should discuss competing explanations for observed treatment effects. Reports should disclose limitations of a study by discussing the weaknesses of animal models and rating scales.

One last counter to optimism bias is transparency. Publication of preclinical toxicology studies is hardly the norm. Such non-publication might have understandable commercial motivations, but it frustrates the ability of assessors to form independent judgments about the safety and promise of an intervention. Researchers should make good faith efforts to publish all preclinical studies before proposing human trials; public and private funding agencies might also establish public databases of preclinical studies. One promising model that might be employed would be the National Gene Vector Laboratory toxicology database.^{lviii}

6. Further Measures Beyond Single Protocols

Though we recognize that each of the proposed practices entails burdens, budgets, and in some instances, proprietary liabilities, we find the counterargument—that these sources of bias remain unchecked—untenable. Our recommendations only address what we consider to be the most tractable problems confronting individual PD FIH studies.

Nevertheless, just as clinical practice is best judged on the basis of community standards, so too should research practices be evaluated. To that end, we suggest two further measures designed to foster the development and articulation of quality standards and practices surrounding FIH studies.

Substantive Criteria

Decisions concerning trial initiation would be greatly enhanced if the field were to articulate clear standards for producing and evaluating preclinical evidence. Questions include the types of cellular and molecular evidence that should be available before initiating studies, effect sizes and consistency of effects in animal models, length of follow-up, clinical and subclinical toxicity testing in animals, and appropriate functional rating scales or other outcome measures with clinical impact. Given the great difficulty encountered in translating PD interventions into clinical applications, guidelines might have limited utility for predicting if a candidate intervention is likely to prove clinically useful. Nevertheless, guidelines might be used to cull agents that do not meet minimum criteria. The Stroke Therapy Academic Industry Roundtable established guidelines in 1999 for the design of preclinical studies.^{lix} Although these guidelines are not “fail-proof,”^{lxi} they provide a framework for designing and evaluating preclinical studies. PD research sponsors might consider whether similar substantive standards might be established for preclinical researchers and referees.

Identifying Best Practices and Research Needs

As noted above, several PD preclinical models are available for preclinical testing. Some members of our workshop questioned whether PD preclinical models had any predictive value whatsoever. This view echoed concerns recently expressed by some Amyotrophic Lateral Sclerosis, Alzheimer’s disease, and Huntington’s disease researchers.^{lxii} Accumulated evidence supports the value of preclinical research for neurological disorders

when appropriate models and hypothesis-driven experimental designs are utilized.^{lxiii} A thorough understanding of the models, their differences and their limitations is nevertheless needed to match the model to the question at hand. This knowledge is also needed to select appropriate outcome measures (functional, anatomical, cellular or molecular) that will provide accumulated evidence of the effects of a therapy.^{liilxiii} Recently, Alzforum hosted a discussion of animal models to discuss shortcomings in mouse models used for neurodegenerative disease research; representatives from the Michael J. Fox Foundation participated.^{lxiv} A similar forum might be established for non-human primates, and for articulating research needs with respect to alternative models. PD preclinical models will be among the many topics discussed in detail on PD Online Research, which is being built by Michael J. Fox Foundation as a web-based, “large-scale self-organizing community of basic and clinical scientists, industry professionals, grantmakers, and financial investors involved in PD research.”^{lxv}

7. Conclusion

In summary, the nature and degree of risk for invasive PD FIH studies puts particular pressure on the requirement that risks be favorably balanced against benefits for human studies. A critical factor in assuring favorable benefit profiles—whether this involves direct, therapeutic benefits or knowledge benefits—is the requirement that preclinical studies be designed and executed with scientific rigor. Toward that end, we have offered several recommendations that center on strengthening internal and external validity, while managing or reducing optimism and publication biases.

Though our workshop centered on PD, our analysis and recommendations could conceivably extend to any research area involving novel and complex agents delivered to the brain. Our recommendations are thus consistent with others aimed at improving the scientific utility and predictive value of experimental neurological interventions. In 1992, for example, PD researchers established the core assessment program for intracerebral transplantation, which aimed at enhancing the interpretability and value of open-label transplant studies.^{lxvi} This framework was subsequently extended to Huntington’s Disease,^{lxvii} and an analogous framework has been devised for surgical treatments of PD.^{lxviii} In 1999, the Stroke Therapy Academic Industry Roundtable convened a working group to “optimally preclinically assess neuroprotective and restorative drugs for acute ischemic stroke.” The group issued a series of recommendations on preclinical^{lxix} and clinical^{lxx} study design.

We nevertheless acknowledge that several additional issues will need to be addressed, perhaps in future workshops, to assure that FIH studies have a favorable risk-benefit balance. These include standards for study design, best practices for reporting and disseminating findings, and how barriers to high quality preclinical research might be overcome. Our recommendations on preclinical study methodology would also be complemented by the development of substantive criteria for initiating studies and procedural guidelines for establishing acceptable risk. At the minimum, our recommendations should stimulate reflection and debate within the wider PD research community.

Acknowledgments

This work was funded by Canadian Institutes of Health Research, States of Mind: Emerging Issues in Neuroethics (NNF 80045). We wish to thank other participants at the workshop, including Andrew Fenton, Eric Racine, Lynette Reid, and Mary Sunderland. We also thank two anonymous referees for their comments on our manuscript, and Kat Duckworth for research assistance.

Financial Support: All financial and material support for this manuscript, regardless of date, was from the Canadian Institutes of Health Research (NNF 80045). Support *unrelated* to this research held by various authors comes from the following sources: CIHR, NINDS, Andrew W. Mellon Foundation, CDC, Kinetics Foundation, M. J. Fox Foundation, Parkinson's Disease Foundation, NIH -RARC base grant RR000167, Health Canada, US EPA, Heart and Stroke Foundation of Canada.

References

1. Ravina B, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment. *Neurology*. 2003; 60:1234–1240. [PubMed: 12707423]
2. Peterson AL, Nutt JG. Treatment of Parkinson's disease with trophic factors. *Neurotherapeutics*. 2008; 5:270–280. [PubMed: 18394569]
3. Nakamura K, Christine CW, Starr PA, Marks WJ Jr. Effects of unilateral subthalamic and pallidal deep brain stimulation on fine motor functions in Parkinson's disease. *Mov Disord*. 2007; 22:619–626. [PubMed: 17230483]
4. Dass B, Olanow W, Kordower JH. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. *Neurology*. 2006; 66:S89–S103. [PubMed: 16717256]
5. Freeman TB, Vawter DE, Leaverton PE, et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. *N Engl J Med*. 1999; 23:988–992. [PubMed: 10498497]
6. Macklin R. The ethical problems with sham surgery in clinical research. *N Engl J Med*. 1999; 341:992–996. [PubMed: 10498498]
7. London AJ, Kadane JB. Placebos that harm: sham surgery controls in clinical trials. *Stat Methods Med Res*. 2002; 11:413–427. [PubMed: 12357587]
8. Kim SY, Holloway RG, Frank S, et al. Volunteering for early phase gene transfer research in Parkinson disease. *Neurology*. 2006; 66:1010–1015. [PubMed: 16540601]
9. Prehn AW, Vawter DE, Gervais KG, et al. Studying neurosurgical implants for Parkinson disease: A question of design. *Neurology*. 2006; 67:1503–1505. [PubMed: 17060588]
10. Master Z, McLeod M, Mendez I. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. *J Med Ethics*. 2007; 33:169–173. [PubMed: 17329391]
11. NIH Guidelines for Research Involving Recombinant DNA Molecules. 2002 April [last accessed 16 October, 2008]. Appendix M. Available at: http://www4.od.nih.gov/oba/rac/guidelines_02/NIH_Gdlnes_Ink_2002z.pdf
12. Recombinant DNA Advisory Committee; Minutes of Meeting June 14 / 15, 2001. [last accessed October 17, 2007]. p. 3-7. Available at: http://www4.od.nih.gov/oba/RAC/minutes/RAC_6-01_Minutes.pdf
13. Grady, D.; Kolata, G. Gene Therapy Used to Treat Patients With Parkinson's. *New York Times*; 2003 August 19.
14. Edelman, S. "Brain-gene Op May Flop; Parkinson's Docs Rip 'Risky' Surgery. *New York Post*; 2003 September 21. p. 8
15. Merkel, R.; Boer, G.; Fegert, J., et al. *Intervening in the Brain: Changing Psyche and Society*. New York: Springer; 2007.
16. Binder DK, Rau GM, Starr PA. Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders. *Neurosurgery*. 2005; 56:722–732. discussion 722-32. [PubMed: 15792511]
17. Sansur CA, Frysinger RC, Pouratian N, et al. Incidence of symptomatic hemorrhage after stereotactic electrode placement. *J Neurosurg*. 2007; 107:998–1003. [PubMed: 17977273]
18. Seijo FJ, Alvarez-Vega MA, Gutierrez JC, et al. Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. *Acta Neurochir (Wien)*. 2007; 149:867–875. [PubMed: 17690838]
19. Goodman RR, Kim B, McClelland S 3rd, et al. Operative techniques and morbidity with subthalamic nucleus deep brain stimulation in 100 consecutive patients with advanced Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 2006; 77:12–17. [PubMed: 16361585]

20. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs. best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. *JAMA*. 2009; 301:63–73. [PubMed: 19126811]
21. Roberts TG, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. *JAMA*. 2004; 292:2130–2140. [PubMed: 15523074]
22. Kimmelman J. Recent developments in gene transfer: risk and ethics. *BMJ*. 2005; 330:79–82. [PubMed: 15637370]
23. Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions. *Curr Gene Ther*. 2007; 7:347–360. [PubMed: 17979681]
24. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. *Lancet*. 2007; 369:2097–2105. [PubMed: 17586305]
25. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. *Neurology*. 2003; 60:69–73. [PubMed: 12525720]
26. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. *Nat Med*. 2003; 9:589–595. [PubMed: 12669033]
27. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology*. 2008; 70:1980–1983. [PubMed: 18401019]
28. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputamenal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. *Lancet Neurology*. 2008; 7:400–408. [PubMed: 18387850]
29. Dell RB, Holleran S, Ramakrishnan R. Sample Size Determination. *ILAR J*. 2002; 43:207–213. [PubMed: 12391396]
30. Guidance for industry and Reviewers. Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Health Volunteers. U.S. DHHS, CBER. 2002 December. Draft Guidance.
31. Committee for Medicinal Products for Human Use (CHMP). *Draft*, Guideline on Requirements for First-in-Man Clinical Trials for Potential High-Risk Medicinal Products. London: 2007 March 22. Doc. Ref.EMA/CHMP/SWP/28367/2007
32. Nuremberg Code. [Last accessed April 1, 2009]. Available at: <http://ohsr.od.nih.gov/guidelines/nuremberg.html>
33. ISSCR Guidelines for the Clinical Translation of Stem Cells". [Last accessed April 1, 2009]. Available at: http://www.isscr.org/clinical_trans/pdfs/ISSCRGLClinicalTrans.pdf
34. Council for International Organisations of Medical Sciences. International ethical guidelines for biomedical research involving human subjects. Guideline 8. [Accessed 16 October 2008]. Available at: http://www.cioms.ch/frame_guidelines_nov_2002.htm
35. Djulbegovic B. Articulating and responding to uncertainties in clinical research. *J Med Philos*. 2007; 32:79–98. [PubMed: 17454416]
36. Hackam DG, Redelmeier DA. Translation of Research Evidence from Animals to Humans. *JAMA*. 2006; 296:1731–1732. [PubMed: 17032985]
37. Ionnidis JPA. Why Most Research Findings are Wrong. *PLoS Med*. 2005; 2:e124. [PubMed: 16060722]
38. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? *Nat Rev Drug Discov*. 2004; 3:711–715. [PubMed: 15286737]
39. Biglan KM, Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. *Semin Neurol*. 2007; 27:106–112. [PubMed: 17390255]
40. Lang AE. Neuroprotection in Parkinson's disease: and now for something completely different? *Lancet Neurol*. 2006; 5:990–991. [PubMed: 17110271]
41. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. *Stroke*. 2001; 32:1349–1359. [PubMed: 11387498]

42. Gladstone DJ, Black SE, Hakim AM. Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke Recovery. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. *Stroke*. 2002; 33:2123–2136. [PubMed: 12154275]
43. Scott S, Kranz JE, Cole J. Design, power, and interpretation of studies in the standard murine model of ALS. *Amyotroph Lateral Scler*. 2008; 9:4–15. [PubMed: 18273714]
44. Dragunow M. The Adult Human Brain in Preclinical Drug Development. *Nature Reviews– Drug Discovery*. 2008; 7:659–666.
45. MacLeod MR, O'Collins T, Howells DW, Donnan GA. Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias. *Stroke*. 2004; 35:1203–1208. [PubMed: 15060322]
46. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. *BMJ*. 2007; 334:197. [PubMed: 17175568]
47. van der Worp HB, de Haan P, Morrema E, Kalkman CJ. Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. *J Neurol*. 2005; 252:1108–1114. [PubMed: 16170651]
48. Bebarta V, Luyten D, Heard K. Emergency medicine animal research: does use of randomization and blinding affect the results? *Acad Emerg Med*. 2003; 10:684–687. [PubMed: 12782533]
49. Crossley NA, Sena E. Empirical Evidence of Bias in the Design of Experimental Stroke Studies: A Meta-epidemiological approach. *Stroke*. 2008; 39:929–934. [PubMed: 18239164]
50. Masliah E, Rockenstein E, Veinbergs I. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. *Science*. 2000; 287:1265–1269. [PubMed: 10678833]
51. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. *J Neurosci*. 2006; 26:41–50. [PubMed: 16399671]
52. Bezard E. A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. *Behav Pharmacol*. 2006; 17:379–382. [PubMed: 16940758]
53. Emborg ME. Nonhuman primate models of Parkinson's disease. *ILAR J*. 2007; 48:339–355. [PubMed: 17712221]
54. Chalmers I, Matthews R. What are the implications of optimism bias in clinical research? *Lancet*. 2006; 36:449–450. [PubMed: 16473106]
55. Lindner MD. Clinical Attrition Due to Biased Preclinical Assessments of Potential Efficacy. *Pharmacology and Therapeutics*. 2007; 115:148–175. [PubMed: 17574680]
56. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. *Neurobiol Dis*. 2007; 26:1–13. [PubMed: 17300945]
57. Macleod MR, et al. Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. *J Cereb Blood Flow Metab*. 2005; 25:713–721. [PubMed: 15703698]
58. NGVL Toxicology Database. [last accessed: October 17, 2008]. Available at: http://www.ngvl.org/include/pages/tox_db.php
59. Stroke Therapy Academic Industry Roundtable (STAIR I). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke*. 1999; 30:2752–2758. [PubMed: 10583007]
60. Gawrylewski A. The trouble with Animal Models. *The Scientist*. 2007; 21:44.
61. Savitz SI, Fisher M. Future of Neuroprotection for Acute Stroke: In the Aftermath of the SAINT Trials. *Ann Neurol*. 2007; 61:396–401. [PubMed: 17420989]
62. Schnabel J. Standard Model. *Nature*. 2008; 454:682–685. [PubMed: 18685674]
63. Capitanio JP, Emborg ME. Contributions of Nonhuman Primates to Neuroscience Research. *Lancet*. 2008; 371:1126–1135. [PubMed: 18374844]
64. Live Discussion: Mice on Trial? Issues in the Design of Drug Studies. Posted 16 June 2008. [Accessed 16 October 2008]. Available at: <http://www.alzforum.org/res/for/journal/transcript.asp?LiveID=168>
65. Personal Communications, Kirsten Carlson. Michael J. Fox Foundation. 2008 October 24.

66. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). *Mov Disord.* 1992; 7:2–13. [PubMed: 1557062]
67. Quinn N, Brown R, Craufurd D, et al. Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). *Mov Disord.* 1996; 11:143–150. [PubMed: 8684383]
68. Defer GL, Widner H, Marié RM, Rémy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). *Mov Disord.* 1999; 14:572–584. [PubMed: 10435493]
69. Stroke Therapy Academic Industry Roundtable (STAIR I). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke.* 1999; 30:2752–2758. [PubMed: 10583007]
70. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. *Stroke.* 2001; 32:1598–1606. [PubMed: 11441207]

Table 1
Methodologies, Samples Sizes, and Practices for Preclinical Studies Leading to PD Trials Involving Trophic Factors and Gene Transfer

References to preclinical supporting studies were obtained from published clinical studies of first-in-kind invasive PD interventions. Whether preclinical studies were published before trial initiation was inferred by comparing publication dates with press reports of trials being initiated or being published. All data were extracted independently by two authors (JK and MEE).

Sample size										Blinding			published before trial	Reference
Species (PD agent)	total	active	max. last time pt (mo.)	sex	allocation	outcome assess.	randomized	a priori power						
AAV-GAD (Kaplitt 2007)	Rat (OH)	49	30 ^a	2	m	1	0	0	0	1	Kaplitt 1994			
	Rat (OH)	20	8	4	m	0	0	0	0	1	Luo 2002			
	Rat (OH)	47	23	4	m	0	0	0	0	1	Luo 2002			
	Rat (OH)	48	24	1	m	0	1	1	0	0	Lee 2005			
	Monkey (M)	20	7	12	f	0	1	0	0	0	Emborg 2006			
AAV-NTN (Marks 2008) ^b	Rat (OH)	34	24	1	m	0	1	0	0	0	Gasmi 2007			
	Rat (OH)	39	15	7	m	0	1	0	0	0	Gasmi 2007			
	Rat (N)	120	80	12	m/f	0	1	0	0	0	Gasmi 2007			
	Rat (N)	90	60	3	m/f	0	1	0	0	0	Gasmi 2007			
	Monkey (N)	13	9 ^c	3	m/f	0	1	0	0	0	Eslamboli 2005			
	Monkey (OH)	18	12 ^c	6	m/f	0	1	0	0	0	Eslamboli 2005			
	Monkey (M)	20	5	10	m	0	1	0	0	0	Kordower 2006			
	Monkey (A)	3	3	8	f	NA	1	0	NA	0	Herzog 2007			
	Monkey (M)	4	2	2	NA	0	0	0	0	0	Bankiewicz 2000			
	Monkey (M)	8	4	72 ^d	m	0	1	0	0	0	Bankiewicz 2006			
GDNF (Nutt 2003) ^e	Monkey (M)	13	6 ^f	1	f	0	1	1	0	NA	Gash 1996			

Sample size		Blinding					published before trial	Reference		
Species (PD agent)	total	active	max. last time pt (mo.)	sex	allocation	outcome assess.			random- ized	<i>a priori</i> power
Monkey (M)	9	6 ^g	3	f	0	1	1	0	NA	Gash 1996
Monkey (M)	30	25	3	f	1	1	1	0	NA	Zhang 1997
GDNF (Gill 2003) ^h	8	4 ⁱ	3	f	0	1	0	0	1	Kordower 2000
Monkey (M)	20	5 ⁱ	3	NA	0	1	0	0	1	Kordower 2000
Monkey (N)	2	2 ⁱ	8	NA	NA	1	0	NA	1	Kordower 2000
Monkey (M)	13	8 ^f	4	f	0	1 ^j	0	0	NA	Grondin 2002

Abbreviations: M=MPTP model; A=Aged model; OH=OHDA model; N= normal animals; NA= Not applicable or not available; m= male; f= female.

^aNotes: Active treatment was AAV-TH

^bReferences Huges et al, 1992 and Starr et al, 2002, that focused on PD diagnoses and DBS targeting for STN respectively, were excluded from this table

^cActive treatment was AAV-GDNF

^dNecropsies timeline: control animals: 24 mo. (n=4): active treatment: 36 mo (n=2), 72 mo. (n=2)

^eReviews by Gash et al., 1998 and Bjorklund 1997 were excluded from this table

^fActive treatments included intraparenchymal and ICV injections

^gTwo ICV monkeys treated with active treatment and 3 controls were also part of experiment

^hReview by Gash et al., 1998 was excluded from this table

ⁱActive treatment was lenti-GDNF

^jDefined as "coded" tapes.

Table 2
Practices That Help Establish Ethical Basis for Initiating First-in-Human Trials

Concern	Practices
Internal Validity	A priori hypothesis stated
	A priori power calculations
	Randomization
	Blinded treatment allocation
	Blinded outcome assessment
	Discussion of missing data
External Validity	Explanation for selection of animal model
	Explanation for selection of rating scale
	Correspondance of trial with preclinical conditions
Optimism and Publication Bias	Critical review of preclinical data
	Full publication of preclinical studies